These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 8709973)

  • 21. Changes in serum lipids and lipoproteins in calcium oxalate stone forming rats treated with sodium pentosan polysulphate.
    Subha K; Sivamurugesan A; Varalakshmi P
    Biochem Int; 1992 Sep; 27(6):1011-8. PubMed ID: 1280138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of urinary macromolecules and chondroitin sulphate on calcium oxalate crystallization in urine.
    Rodgers AL; Ball D; Harper W
    Scanning Microsc; 1994 Mar; 8(1):71-7. PubMed ID: 7973501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of monosodium urate on the capacity of urine, chondroitin sulphate and heparin to inhibit calcium oxalate crystal growth and aggregation.
    Ryall RL; Harnett RM; Marshall VR
    J Urol; 1986 Jan; 135(1):174-7. PubMed ID: 3079836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of chondroitin sulphate and heparin on the growth and agglomeration of calcium oxalate monohydrate crystals in vitro.
    Gjaldbaek JC
    Clin Chim Acta; 1982 Apr; 120(3):363-5. PubMed ID: 6804134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The antiheparin effect of a heparinoid, pentosan polysulphate. Investigation of a mechanism.
    Scully MF; Kakkar VV
    Biochem J; 1984 Mar; 218(3):657-65. PubMed ID: 6202294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urinary crystal growth: effect of inhibitor mixtures.
    Werness PG; Bergert JH; Lee KE
    Clin Sci (Lond); 1981 Oct; 61(4):487-91. PubMed ID: 6169479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of pH on the urinary inhibition of calcium oxalate crystal growth.
    Tiselius HG
    Br J Urol; 1981 Oct; 53(5):470-4. PubMed ID: 6793122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of two new semi-synthetic glycosaminoglycans (G871, G872) on the zeta potential of calcium oxalate crystals and on growth and agglomeration.
    Cao LC; Boevé ER; Schröder FH; Robertson WG; Ketelaars GA; de Bruijn WC
    J Urol; 1992 Jun; 147(6):1643-6. PubMed ID: 1593714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The preventive effect of sodium pentosan polysulfate against renal stone formation in hyperoxaluric rats.
    Nakatani T; Ishii K; Yoneda Y; Kamikawa S; Kanazawa T; Sugimoto T; Osswald H
    Urol Res; 2002 Oct; 30(5):329-35. PubMed ID: 12389123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modifiers of calcium oxalate crystallization found in urine. I. Studies with a continuous crystallizer using an artificial urine.
    Robertson WG; Scurr DS
    J Urol; 1986 Jun; 135(6):1322-6. PubMed ID: 2423714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alterations in some risk factors and urinary enzymes in urolithiatic rats treated with sodium pentosan polysulphate.
    Subha K; Varalakshmi P
    Biochem Mol Biol Int; 1993 Feb; 29(2):271-80. PubMed ID: 7684293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Studies on calcium oxalate monohydrate crystallization: influence of inhibitors.
    Grases F; Kroupa M; Costa-Bauzá A
    Urol Res; 1994; 22(1):39-43. PubMed ID: 7521089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glycosaminoglycans, uric acid and calcium oxalate urolithiasis.
    Grases F; Costa-Bauzá A; March JG; Masárová L
    Urol Res; 1991; 19(6):375-80. PubMed ID: 1759332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of some urinary stone inhibitors on membrane interaction potentials of stone crystals.
    Mandel NS; Mandel GS; Hasegawa AT
    J Urol; 1987 Sep; 138(3):557-62. PubMed ID: 2442419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Binding of glycosaminoglycans to sodium urate and uric acid crystals.
    Fellström B; Lindsjö M; Danielson BG; Ljunghall S; Wikström B
    Clin Sci (Lond); 1986 Jul; 71(1):61-4. PubMed ID: 2423287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new approach to studying inhibitors of calcium oxalate crystal growth.
    Hennequin C; Lalanne V; Daudon M; Lacour B; Drueke T
    Urol Res; 1993 Mar; 21(2):101-8. PubMed ID: 8389069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of renal calcium stone disease with the synthetic glycosaminoglycan pentosan polysulphate.
    Fellström B; Backman U; Danielson B; Wikström B
    World J Urol; 1994; 12(1):52-4. PubMed ID: 7516780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of sodium pentosan polysulphate on tissue lipids in control and glycollate treated rats.
    Subha K; Varalakshmi P
    Pharmacol Res; 1993; 27(4):289-97. PubMed ID: 7690133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of heparin cofactor II as the principal plasma cofactor for the antithrombin activity of pentosan polysulphate (SP54).
    Scully MF; Kakkar VV
    Thromb Res; 1984 Oct; 36(2):187-94. PubMed ID: 6209821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of trace metals on the inhibition of calcium oxalate crystallization.
    Muñoz JA; Valiente M
    Urol Res; 2005 Aug; 33(4):267-72. PubMed ID: 15937709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.